MDGL (Madrigal Pharmaceuticals, Inc.) Stock Financials & Earnings

MDGLMadrigal Pharmaceuticals, Inc.

Mkt Cap$10B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$958M

Net Income (TTM)-$288M

EPS (TTM)-$12.87

Free Cash Flow (TTM)-$190M

Gross Margin94.1%

Op. Margin-31.3%

Net Margin-30.1%

FCF Margin-19.8%

P/S Ratio (TTM)10.4x

P/E Ratio (TTM)—

YoY Rev Growth+432.1%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$78M
Q2 23	$0	$0	-$86M
Q3 23	$0	$0	-$99M
Q4 23	$0	$0	-$117M
Q1 24	$0	$0	-$152M
Q2 24	$15M	$14M	-$163M
Q3 24	$62M	$60M	-$116M
Q4 24	$103M	$100M	-$67M
Q1 25	$137M	$133M	-$79M
Q2 25	$213M	$204M	-$47M
Q3 25	$287M	$269M	-$114M
Q4 25	$321M	$297M	-$60M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$62M	$16M	—
Q2 23	$69M	$18M	—
Q3 23	$71M	$28M	—
Q4 23	$71M	$47M	—
Q1 24	$71M	—	$81M
Q2 24	$71M	—	$105M
Q3 24	$69M	$108M	—
Q4 24	$26M	—	$141M
Q1 25	$44M	—	$168M
Q2 25	$54M	—	$197M
Q3 25	$174M	$209M	—
Q4 25	$116M	—	$240M

Revenue Segments

Quarter	Reportable Segment
Q2 25	$213M
Q3 25	$287M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$113M	$216M	$329M
Q2 23	$77M	$221M	$298M
Q3 23	$62M	$170M	$232M
Q4 23	$100M	$534M	$634M
Q1 24	$623M	$437M	$1.1B
Q2 24	$495M	$563M	$1.1B
Q3 24	$233M	$766M	$999M
Q4 24	$100M	$826M	$926M
Q1 25	$184M	$659M	$843M
Q2 25	$186M	$611M	$797M
Q3 25	$296M	$814M	$1.1B
Q4 25	$199M	$785M	$984M

Shares Outstanding

Revenue Per Employee

Revenue / Employee